Brought to you by 
ChemoCentryx and Forest develop new CCR1 compounds; deal ends
29 Oct 2020
Executive Summary
Chemokine-based drug discovery company ChemoCentryx and Forest Laboratories have entered into an agreement to develop and sell small-molecule compounds to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and multiple sclerosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ChemoCentryx and Forest develop new CCR1 compounds; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice